奥洛兹美医疗公司已正式确认，根据最新发布的、针对2029年IPAY计划的医保药品价格谈判计划拟议规则草案，公司预计其特许权使用费收入至少在2035年之前不会受到显著影响，影响程度预计为零或极小。这一评估为投资者提供了关于公司长期收入前景的明确指引，缓解了市场对潜在政策变动可能冲击其核心收入流的担忧。
奥洛兹美医疗公司已正式确认，根据最新发布的、针对2029年IPAY计划的医保药品价格谈判计划拟议规则草案，公司预计其特许权使用费收入至少在2035年之前不会受到显著影响，影响程度预计为零或极小。这一评估为投资者提供了关于公司长期收入前景的明确指引，缓解了市场对潜在政策变动可能冲击其核心收入流的担忧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.